长链非编码RNA（lncRNA）相关免疫基因（lrRIGs）在肺腺癌（LUAD）的发展和进展中起着至关重要的作用。然而，尚未确定基于lrRIGs的可靠预后标志。我们使用癌症基因组图谱（TCGA）数据库筛选与LUAD预后相关的lrRIGs，然后通过生物信息学方法建立了一个由CD79A、INHA、SHC3、LIFR、TNFRSF11A、GPI、F2RL1、SEMA7A和WFDC2组成的新颖九基因签名。根据这个基因签名得出的风险评分将LUAD患者分为低风险组和高风险组。后者的总生存期（O.S.）明显较差。使用风险评分和其他独立预后要素开发了一个预后图，展示了在预测LUAD患者的O.S.率方面出色的表现。我们观察到低风险组和高风险组之间的免疫细胞亚型浸润和免疫治疗、化疗反应显著不同。总体而言，基于这个基因签名的分层可以用于指导更好的治疗管理，并改善LUAD患者的预后。© 2023. 作者以独家许可授予施普林格自然有限公司。

Long non-coding RNAs (lncRNAs)-related immune genes (lrRIGs) play a crucial role in the development and progression of lung adenocarcinoma (LUAD). However, reliable prognostic signatures based on lrRIGs have not yet been identified.We screened lrRIGs associated with the prognosis of LUAD using The Cancer Genome Atlas (TCGA) database and then established a novel prognostic nine-gene signature composed of CD79A, INHA, SHC3, LIFR, TNFRSF11A, GPI, F2RL1, SEMA7A and WFDC2 through bioinformatic approaches. A risk score derived from this gene signature was used to divide LUAD patients into the low- and high-risk groups. The latter was confirmed to have markedly worse overall survival (O.S.). A nomogram was developed using the risk score and other independent prognostic elements, demonstrating excellent performance in predicting the O.S. rate of LUAD patients.We observed that the infiltration of diverse immune cell subtypes and response to immunotherapy and chemotherapy significantly differed between the low- and high-risk groups.Overall, stratification based on this gene signature could be used to guide better therapeutic management and improve outcomes for LUAD patients.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.